Marcus Lind

List of Publications by Year
in descending order

97 papers	5,078 citations	126907 33 h-index	95266 68 g-index
98 all docs	98 docs citations	98 times ranked	6618 citing authors

#	Article	IF	Citations
1	Evaluation of Effects of Continuous Glucose Monitoring on Physical Activity Habits and Blood Lipid Levels in Persons With Type 1 Diabetes Managed With Multiple Daily Insulin Injections: An Analysis Based on the GOLD Randomized Trial (GOLD 8). Journal of Diabetes Science and Technology, 2024, 18, 89-98.	2.2	2
2	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	2.2	69
3	Evaluation of Reference Metrics for Continuous Glucose Monitoring in Persons Without Diabetes and Prediabetes. Journal of Diabetes Science and Technology, 2022, 16, 373-382.	2.2	15
4	Glycemic Control and Risk of Sepsis and Subsequent Mortality in Type 2 Diabetes. Diabetes Care, 2022, 45, 127-133.	8.6	7
5	Risk factors for nephropathy in persons with type 1 diabetes: a population-based study. Acta Diabetologica, 2022, , 1.	2.5	3
6	Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections. Journal of Diabetes and Its Complications, 2022, 36, 108110.	2.3	1
7	Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2644-2651.	3.6	10
8	<scp>Long-term</scp> efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled <scp>52-week</scp> outcomes from the <scp>DEPICT</scp>-1 and -2 studies. Diabetes, Obesity and Metabolism, 2021, 23, 549-560.	4.4	21
9	LDL cholesterol level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes mellitus: A nationwide cohort study. Journal of Internal Medicine, 2021, 289, 873-886.	6.0	10
10	Variables associated with insulin production in persons with type 2 diabetes treated with multiple daily insulin injections. Primary Care Diabetes, 2021, 15, 607-613.	1.8	0
11	Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI. Diabetes Care, 2021, 44, 141-149.	8.6	19
12	The majority of people with type <scp>1</scp> diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the <scp>GOLD</scp> randomized trial (<scp>GOLD-5</scp>). Diabetes, Obesity and Metabolism, 2021, 23, 619-630.	4.4	9
13	Prevalence and impact of chronic dysglycemia in intensive care unit patients—A retrospective cohort study. Acta Anaesthesiologica Scandinavica, 2021, 65, 82-91.	1.6	6
14	Effects of nutrition education using a food-based approach, carbohydrate counting or routine care in type 1 diabetes: 12 months prospective randomized trial. BMJ Open Diabetes Research and Care, 2021, 9, e001971.	2.8	11
15	Early and long-term prognosis in patients with and without type 2 diabetes after carotid intervention: a Swedish nationwide propensity score matched cohort study. Cardiovascular Diabetology, 2021, 20, 85.	6.8	2
16	Trajectories in HbA1c and other risk factors among adults with type 1 diabetes by age at onset. BMJ Open Diabetes Research and Care, 2021, 9, e002187.	2.8	13
17	Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial. Diabetes Care, 2021, 44, 1604-1612.	8.6	27
18	Characteristics of Continuous Glucose Monitoring Metrics in Persons with Type 1 and Type 2 Diabetes Treated with Multiple Daily Insulin Injections. Diabetes Technology and Therapeutics, 2021, 23, 425-433.	4.4	3

#	Article	IF	Citations
19	Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes Care, 2021, 44, 2231-2237.	8.6	51
20	Risk factors and incidence over time for lower extremity amputations in people with type 1 diabetes: an observational cohort study of 46,088 patients from the Swedish National Diabetes Registry. Diabetologia, 2021, 64, 2751-2761.	6.3	13
21	Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study. Cardiovascular Diabetology, 2021, 20, 202.	6.8	19
22	Renal Complications and Duration of Diabetes: An International Comparison in Persons with Type 1 Diabetes. Diabetes Therapy, 2021, 12, 3093-3105.	2.5	3
23	Incidence and risk factors for mortality and end-stage renal disease in people with type 2 diabetes and diabetic kidney disease: a population-based cohort study in the UK. BMJ Open Diabetes Research and Care, 2021, 9, e002146.	2.8	32
24	Impact of chronic kidney disease definition on assessment of its incidence and risk factors in patients with newly diagnosed type 1 and type 2 diabetes in the UK: A cohort study using primary care data from the United Kingdom. Primary Care Diabetes, 2020, 14, 381-387.	1.8	19
25	Impact of CKD Progression on Cardiovascular Disease Risk in a Contemporary UK Cohort of Individuals With Diabetes. Kidney International Reports, 2020, 5, 1651-1660.	0.8	19
26	The Association Between HbA1c and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4). Diabetes Care, 2020, 43, 2017-2024.	8.6	34
27	Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel design, open label, Phase 3 trial. Diabetes, Obesity and Metabolism, 2020, 22, 957-968.	4.4	4
28	Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovascular Diabetology, 2020, 19, 9.	6.8	70
29	Long term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT 2 study): 52 week results from a randomized controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 1516-1526.	4.4	38
30	HbA$_{1c}$ level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ: British Medical Journal, 2019, 366, l4894.	2.3	109
31	Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections. Diabetes Therapy, 2019, 10, 2115-2130.	2.5	15
32	Risk Factors for Atrial Fibrillation in People With Type 1 Diabetes: An Observational Cohort Study of 36,258 Patients From the Swedish National Diabetes Registry. Diabetes Care, 2019, 42, 1530-1538.	8.6	16
33	Use of fast acting insulin aspart in insulin pump therapy in clinical practice. Diabetes, Obesity and Metabolism, 2019, 21, 2039-2047.	4.4	41
34	Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. Diabetes Care, 2019, 42, 1464-1472.	8.6	5
35	Excess risk of lower extremity amputations in people with type 1 diabetes compared with the general population: amputations and type 1 diabetes. BMJ Open Diabetes Research and Care, 2019, 7, e000602.	2.8	17
36	Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI liraglutide study 5). Obesity Science and Practice, 2019, 5, 130-140.	1.9	8

#	Article	IF	Citations
37	Glycated Hemoglobin A1c Levels in Type 1 Diabetes Mellitus and Outcomes After Myocardial Infarction. Circulation, 2019, 139, 2380-2382.	1.6	2
38	BMI, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes: Findings Against an Obesity Paradox. Diabetes Care, 2019, 42, 1297-1304.	8.6	47
39	Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2. Diabetes Care, 2019, 42, 1081-1087.	8.6	40
40	Glycaemic control and excess risk of major coronary events in patients with type 2 diabetes: a population-based study. Open Heart, 2019, 6, e000967.	2.3	5
41	Investigation of early signs of systolic and diastolic dysfunction among persons with type 1 diabetes. Open Heart, 2019, 6, e001020.	2.3	0
42	Contrasting Associations of Body Mass Index and Hemoglobin A1c on the Excess Risk of Acute Myocardial Infarction and Heart Failure in Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2019, 8, e013871.	3.7	12
43	Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes. Journal of Clinical Hypertension, 2019, 21, 105-115.	2.0	12
44	Body mass index as a risk factor for coronary events and mortality in patients with type 1 diabetes. Open Heart, 2018, 5, e000727.	2.3	11
45	A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). Diabetes Technology and Therapeutics, 2018, 20, 274-284.	4.4	88
46	BMI and Mortality in Patients With New-Onset Type 2 Diabetes: A Comparison With Age- and Sex-Matched Control Subjects From the General Population. Diabetes Care, 2018, 41, 485-493.	8.6	29
47	Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3). BMJ Open Diabetes Research and Care, 2018, 6, e000464.	2.8	18
48	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	8.6	190
49	Excess risk of hospitalisation for heart failure among people with type 2 diabetes. Diabetologia, 2018, 61, 2300-2309.	6.3	31
50	Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. JAMA - Journal of the American Medical Association, 2017, 317, 379.	7.4	520
51	A Clinical Trial of the Accuracy and Treatment Experience of the Flash Glucose Monitor FreeStyle Libre in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 164-172.	4.4	143
52	Contemporary risk estimates of three HbA1cvariables in relation to heart failure following diagnosis of type 2 diabetes. Heart, 2017, 103, 353-358.	2.9	8
53	Risk factors for diabetic macular oedema in type 2 diabetes: A case-control study in a United Kingdom primary care setting. Primary Care Diabetes, 2017, 11, 288-296.	1.8	8
54	Prevalence of primary aldosteronism among patients with type 2 diabetes. Clinical Endocrinology, 2017, 87, 233-241.	2.4	12

#	Article	IF	Citations
55	Adherence of self-monitoring of blood glucose in persons with type 1 diabetes in Sweden. BMJ Open Diabetes Research and Care, 2017, 5, e000342.	2.8	70
56	Long‐term excess risk of stroke in people with Type 2 diabetes in Sweden according to blood pressure level: a population‐based case–control study. Diabetic Medicine, 2017, 34, 522-530.	2.3	16
57	Glycaemic control and excess risk of ischaemic and haemorrhagic stroke in patients with type 1 diabetes: a cohort study of 33 453 patients. Journal of Internal Medicine, 2017, 281, 261-272.	6.0	19
58	Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. Lancet Diabetes and Endocrinology,the, 2017, 5, 799-807.	11.4	53
59	Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes. Heart, 2017, 103, 1687-1695.	2.9	41
60	Atrial fibrillation and type 1 diabetes â€" Authors' reply. Lancet Diabetes and Endocrinology,the, 2017, 5, 937.	11.4	0
61	Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden. Diabetes Therapy, 2016, 7, 321-333.	2.5	7
62	Design and Methods of a Randomized Trial of Continuous Glucose Monitoring in Persons With Type 1 Diabetes With Impaired Glycemic Control Treated With Multiple Daily Insulin Injections (GOLD Study). Journal of Diabetes Science and Technology, 2016, 10, 754-761.	2.2	18
63	Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. American Heart Journal, 2016, 182, 111-118.	2.7	15
64	The relationship between three eGFR formulas and hospitalization for heart failure in 54Â486 individuals with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2016, 32, 730-735.	4.0	17
65	Glycemic Control, Renal Complications, and Current Smoking in Relation to Excess Risk of Mortality in Persons With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 1006-1014.	2.2	14
66	Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference. Journal of Diabetes Science and Technology, 2016, 10, 876-884.	2.2	23
67	Risk factors for diabetic retinopathy in people with Type 2 diabetes: A case–control study in a UK primary care setting. Primary Care Diabetes, 2016, 10, 300-308.	1.8	18
68	Decreased eGFR as a Risk Factor for Heart Failure in 13 781 Individuals With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 131-136.	2.2	12
69	Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial). Primary Care Diabetes, 2015, 9, 15-22.	1.8	16
70	Glycemic Control and Excess Mortality in Type 1 Diabetes. New England Journal of Medicine, 2015, 372, 879-881.	27.0	36
71	Predicting the Effectiveness of Insulin Pump Therapy on Glycemic Control in Clinical Practice: A Retrospective Study of Patients with Type 1 Diabetes from 10 Outpatient Diabetes Clinics in Sweden over 5 Years. Diabetes Technology and Therapeutics, 2015, 17, 21-28.	4.4	23
72	Recognition of Incident Diabetes Mellitus During an Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 260-267.	2.2	16

#	Article	IF	Citations
73	Excess Mortality among Persons with Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 1720-1732.	27.0	777
74	Contemporary Risk Estimates of Three HbA1c Variables for Myocardial Infarction in 101,799 Patients Following Diagnosis of Type 2 Diabetes. Diabetes Care, 2015, 38, 1481-1486.	8.6	10
75	Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes and Endocrinology,the, 2015, 3, 876-885.	11.4	69
76	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ, The, 2015, 351, h5364.	6.0	53
77	Age at diagnosis predicts deterioration in glycaemic control among children and adolescents with type 1 diabetes. BMJ Open Diabetes Research and Care, 2014, 2, e000039.	2.8	48
78	The association between <scp>BMI</scp> and hospitalization for heart failure in 83Â021 persons with TypeÂ2 diabetes: a populationâ€based study from the Swedish National Diabetes Registry. Diabetic Medicine, 2014, 31, 586-594.	2.3	25
79	Glycemic Control and Excess Mortality in Type 1 Diabetes. New England Journal of Medicine, 2014, 371, 1972-1982.	27.0	717
80	A Clinical Trial of the Accuracy and Treatment Experience of the Dexcom G4 Sensor (Dexcom G4) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4 with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2014, 16, 759-767.	4.4	76
81	Changes in HbA1c and frequency of measuring HbA1c and adjusting glucose-lowering medications in the 10Âyears following diagnosis of type 2 diabetes: a population-based study in the UK. Diabetologia, 2014, 57, 1586-1594.	6.3	15
82	The Association between HbA1c, Fasting Glucose, 1-Hour Glucose and 2-Hour Glucose during an Oral Glucose Tolerance Test and Cardiovascular Disease in Individuals with Elevated Risk for Diabetes. PLoS ONE, 2014, 9, e109506.	2.5	38
83	Relationship Between Overweight and Obesity With Hospitalization for Heart Failure in 20,985 Patients With Type 1 Diabetes. Diabetes Care, 2013, 36, 2857-2861.	8.6	39
84	Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. Diabetologia, 2013, 56, 2601-2608.	6.3	142
85	Insulin Pumpâ€"Long-Term Effects on Glycemic Control: An Observational Study at 10 Diabetes Clinics in Sweden. Diabetes Technology and Therapeutics, 2013, 15, 302-307.	4.4	32
86	Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thrombosis Research, 2012, 129, 32-35.	1.7	65
87	Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Primary Care Diabetes, 2012, 6, 41-46.	1.8	65
88	The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Primary Care Diabetes, 2012, 6, 53-59.	1.8	35
89	Incretin therapy and its effect on body weight in patients with diabetes. Primary Care Diabetes, 2012, 6, 187-191.	1.8	15
90	The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia, 2012, 55, 2946-2953.	6.3	84

#	Article	IF	Citations
91	Availability of insulin pump therapy in clinical practice. Diabetic Medicine, 2012, 29, 1055-1059.	2.3	12
92	Glycaemic control and incidence of heart failure in 20â€ˆ985 patients with type 1 diabetes: an observational study. Lancet, The, 2011, 378, 140-146.	13.7	222
93	Effect on Glycemic Control by Short- and Long-Term Use of Continuous Glucose Monitoring in Clinical Practice. Journal of Diabetes Science and Technology, 2011, 5, 1472-1479.	2.2	15
94	The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia, 2010, 53, 1093-1098.	6.3	75
95	The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables. PLoS ONE, 2009, 4, e4412.	2.5	61
96	The Effect of Insulin Lispro on Glycemic Control in a Large Patient Cohort. Diabetes Technology and Therapeutics, 2009, 11, 51-56.	4.4	9
97	A systematic review of HbA1c variables used in the study of diabetic complications. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2008, 2, 282-293.	3.6	45